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Benzodiazepines bind not only to GABAA-receptors, but also to
the structurally and pharmacologically distinct peripheral benzo-
diazepine receptor (PBR) (Braestrup and Squires, 1977). In
contrast to GABAA-receptors, the PBR exhibits high affinity for
the benzodiazepine Ro5-4864, the isoquinoline carboxamide PK
11195 and the indoleacetamide FGIN-1-27 (Le Fur et al, 1983;
Kozikowski et al, 1993), but only a very low affinity for the benzo-
diazepine clonazepam (Wang et al, 1984a). PBR is highly
expressed in steroid-producing tissues such as ovary, testis,
adrenal and placenta (Gavish et al, 1999; Beurdeley-Thomas et al,
2000). In contrast, PBR is present only at low densities in skeletal
muscle, the gastrointestinal tract, and in much of the brain (Verma
and Snyder, 1989; Gavish et al, 1992). Interestingly, PBR was
shown to be overexpressed in several tumours including those of
the colon, brain, breast, ovary and liver (Katz et al, 1990a, 1990b;
Cornu et al, 1992; Batra and Iosif, 1998; Venturini et al, 1998;
Carmel et al, 1999; Hardwick et al, 1999). PBR is mainly localized
in the mitochondria (Anholt et al, 1986), but has also been
detected in the plasma membrane (Garnier et al, 1993) and nucleus
(Hardwick et al, 1999). Due to the pharmacological effects of
specific PBR ligands and the cellular and subcellular localization
of PBR, a broad spectrum of putative functions has been attributed
to PBR such as regulation of steroid production (Papadopoulos,
1993), inflammatory response (Torres et al, 1999), insulin secre-
tion (Marchetti et al, 1996b), mitochondrial respiration (Hirsch
et al, 1989; Krueger, 1995), cell differentiation (Canat et al, 1993)
and cell proliferation. Proliferation of various tumours including
breast cancer (Beinlich et al, 1999; Carmel et al, 1999), melanoma
(Landau et al, 1998), testis (Garnier et al, 1993) and astrocytoma
(Neary et al, 1995) was shown to be inhibited by PBR ligands at
micromolar concentrations. In contrast, at nanomolar concentrations
PBR-specific ligands were mitogenic (Laird et al, 1989; Ikezaki and
Black, 1990; Beinlich et al, 1999; Hardwick et al, 1999). However,
the underlying mechanisms of the growth-modulating actions of
PBR ligands are still unknown.
Tumour cell growth is characterized by an imbalance between
cell division and cell death. A common step in tumorigenesis is
the loss of the capability of cells to undergo apoptosis. The local-
ization of PBR in the mitochondrial membrane and its implica-
tion in the permeability transition pore (Zorov, 1996; Fennell
et al, 2001) suggest that the PBR takes part in the regulation of
the mitochondrial permeability and induction of apoptosis.
However, the role of PBR in the regulation of apoptosis is not yet
understood. Specific PBR ligands were shown to either induce
apoptosis directly (Marchetti et al, 1996a; Tanimoto et al, 1999;
Fischer et al, 2001), or to facilitate apoptosis by inhibiting the anti-
apoptotic effects of BCL-2 (Hirsch et al, 1998; Larochette et al,
1999; Ravagnan et al, 1999). In contrast, apoptosis-protective
effects of PBR ligands have been reported as well (Bono et al,
1999). Besides their putative role in the regulation of apoptosis,
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doi: 10.1054/ bjoc.2001.2181, available online at http://www.idealibrary.com on  http://www.bjcancer.comPBR ligands were shown to induce cell cycle arrest in the G1/G0-
and G2/M-phase in breast carcinoma and melanoma cell lines
(Landau et al, 1998; Carmel et al, 1999). Similarly, the new
benzazepine BBL22, classified as a PBR-specific ligand, induc-
ed arrest in the G2/M-phase in different tumour cell lines of
epithelial or haematopoietic origin followed by an induction of
apoptosis (Xia et al, 2000). 
As PBR was shown to be overexpressed in colorectal tumours
(Katz et al, 1990b), PBR may well play a functional role in colo-
rectal carcinogenesis. However, an involvement of PBR in
colorectal cancer growth has not been investigated so far. In this
study we show that specific PBR ligands inhibit proliferation of
colorectal cancer cells, which is associated with an induction of
apoptosis and cell cycle arrest. 
MATERIALS AND METHODS 
Cell culture 
The human colorectal adenocarcinoma cell lines HT29 and
Colo320 DM (neurorendocrine-differentiated) were grown in
RPMI 1640 medium supplemented with 10% fetal calf serum. The
human colorectal adenocarcinoma cell line LS174T was grown in
Dulbecco’s minimal essential medium supplemented with 10%
fetal calf serum. Cell lines were cultured in a humidified atmos-
phere containing 5% CO2 at 37˚C (Hanski et al, 2000). 
Surgically resected specimens of primary colorectal carcinomas
(3 rectum, 3 colon) were obtained from 4 female and 2 male patients
who underwent surgery in the Department of Surgery, Benjamin
Franklin University Hospital, Free University Berlin. The human
tumour material was used according to the standards set by the
Ethical Committee of the Benjamin Franklin University Hospital,
Free University of Berlin. The age of the patients ranged from 23
to 78 years. Primary cell cultures were prepared by mechanical
dissection using a Medimachine with 50 µ m Medicons (Becton
Dickinson, Heidelberg, Germany) according to the manufacturer’s
instructions. Isolated cells were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum, penicillin (100 U ml–1),
and streptomycin (100 µ g ml–1) and cultured in a humidified
atmosphere containing 5% CO2 at 37˚C (Höpfner et al, 1998). 
Reverse transcriptase chain reaction (RT-PCR) 
RNA isolation, reverse transcription, and PCR reactions were
carried out as described (Glassmeier et al, 1998). Amplification
consisted of 38 cycles with the following conditions for denatura-
tion, annealing and extension: 94˚C for 45 s, 60˚C for 45 s and 72˚C
for 2 min. The primers for amplification of cDNA were designed
using the PRIMER program (Whitehead Institute for Biomedical
Research, Cambridge, MA, USA) based on the cDNA sequences of
human 18 kDa PBR subunit obtained from the GenBank (accession
number: M36035). Primers for amplification were: 
Forward: 5′ -CACGCTCTACTCAGCCATGG-3′
Reverse: 5′ -GCAGTAGTTGAGTGTGGTCGC-3′
The expected PCR product size was 298 bp. PCR products were
sequenced on an ABI 310 sequencer (Applied Biosystems, Foster
City, CA, USA) and specificity of the transcripts was confirmed
by the NCBI (National Center for Biotechnology Information,
Bethesda, MD, USA) BLASTIN 2.0 search program (Altschul
et al, 1997). 
Flow cytometry 
Cells were trypsinized, washed twice with phosphate-buffered
NaCl solution (PBS; 140 mM NaCl, 10 mM Na2HPO4, 2.6 mM KCl,
1.4 mM KH2PO4, pH 7.4) and immunoassayed, as described
(Maaser et al, 1999; Stoebner et al, 1999). Cells were fixed in 4%
paraformaldehyde for 30 min at room temperature, washed once with
PBS, and permeabilized for 10 min in PBS containing 0.1% saponin
(Merck, Darmstadt, Germany) and 1% bovine serum albumin (BSA;
Sigma, Deisenhofen, Germany). Cells were incubated for 1 h at room
temperature with primary anti-PBR antibody 8D7 (5 µ g ml–1 in PBS
containing 0.1% saponin, 1% BSA) (Dussossoy et al, 1996) or
isotypic control mouse IgG1 (DAKO, Hamburg, Germany), respec-
tively. Cells were washed twice with PBS containing 0.03% saponin
and then incubated with 4 µ g ml–1 secondary Alexa™ 488-labelled
goat-anti-mouse IgG antibody (Molecular Probes, Eugene, OR,
USA) for 1 h at room temperature. Fluorescence was detected by
flow cytometry on a FACSCalibur (Becton Dickinson, Heidelberg,
Germany) and analysed using CellQuest software. 
Immunofluorescence labelling and confocal
microscopy 
Cells were plated on glass cover slips for 24 h. Cells were stained
with the mitochondrial dye CMTMRos (100 nM in medium, 30
min, 37˚C) (Molecular Probes, Eugene, OR, USA). After washing
with PBS, the samples were fixed by incubation with 4%
paraformaldehyde in PBS for 30 min at room temperature, washed
with PBS, and permeabilized with cold methanol (20 min, –20˚C)
followed by acetone (10 s, –20˚C). Cells were incubated for 1 h at
room temperature with primary anti-PBR monoclonal antibody
8D7 (5 µ g ml–1 in PBS) (Dussossoy et al, 1996) or isotypic control
mouse IgG1 (DAKO, Hamburg, Germany), respectively. There-
after, cells were washed with PBS twice and incubated with
4 µ g ml–1 secondary AlexaTM 488-labelled goat-anti-mouse IgG
antibody (Molecular Probes, Eugene, OR, USA) for 1 h at room
temperature. Fluorescence and transmission images were obtained
using the inverted confocal microscope LSM 410 with a 63x /1,2 W
Korr objective (Zeiss, Oberkochen, Germany). 
Immunohistochemistry 
23 paraffin-embedded colorectal carcinomas were studied. These
were 1 well differentiated, 13 moderately differentiated, and 9 poorly
differentiated cancers. 2 µ m sections of the tumours were deparaf-
finized and rehydrated in a series of alcohol solutions of decreasing
concentrations (Grabowski et al, 2000, 2001). Then sections were
transferred into a robotic machine (Chemo-mate, DAKO, Heidelberg,
Germany) and staining procedure was automatically performed under
following standard conditions. Sections were incubated with the anti-
PBR antibody 8D7 (0.5 µ g ml–1) for 30 min at room temperature.
After washing samples were incubated with the second anti-mouse
IgG (1:20 dilution) (DAKO, Heidelberg, Germany) for 30 min at
room temperature. The APAAP complex (DAKO, Heidelberg,
Germany) was incubated for 30 min at a dilution 1:50 in RPMI
medium containing 10% fetal calf serum and 1% sodium azide.
Staining was detected using fast-red system (DAKO, Heidelberg,
Germany) and samples were counterstained with haemalaun. 
Cell proliferation assay 
The ability of the PBR ligands to modulate cell proliferation was
studied using the crystal violet method (Gillies et al, 1986). In
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well–1 (HT29 and Colo320 DM) or 2000 cells well–1 (LS174T).
After 72 h the PBR ligands FGIN-1-27, PK 11195 (Tocris, Bristol,
UK), or Ro5-4685 (Sigma, Deisenhofen, Germany) were added at
concentrations of 1 nM to 100 µ M. The FGIN–1-52 (Kozikowski
et al, 1993) or the GABAA receptor ligand clonazepam (Sigma,
Deisenhofen, Germany) were used as controls. Each concentration
group consisted of 10 wells. The incubation medium was changed
every day. Cell quantification was performed after 0, 24, 48, 72
and 96 h of incubation. Cells of each well were washed (200 µ l
PBS) and fixed (100 µ l, 1% glutaraldehyde in PBS for 15 min at
room temperature). After another washing step (200 µ l PBS), cells
were stained with 0.1% crystal violet in PBS for 30 min at room
temperature. The unbound dye was removed by washing with H2O
for 30 min. Crystal violet which had absorbed onto the cells was
solubilized with 100 µ l 0.2% Triton-X–100 in PBS for at least 24
h at 37˚C. The crystal violet containing solution was measured
spectrometrically at 570 nm using an ELISA-Reader. In the range
of 500 to 20 000 cells well–1, the measured extinction was a linear
function of the cell number (Höpfner et al, 1998). 
Mitochondrial membrane potential measurement 
Cells were incubated with medium containing FGIN-1-27,
PK 11195, Ro5-4685, FGIN–1-52, or clonazepam at concentra-
tions from 10 µ M to 100 µ M for 6 h to 16 h. Changes in mito-
chondrial membrane potential (∆ Ψ M) were assessed using the
fluorogenic dye JC–1 (Molecular Probes, Eugene, OR, USA). The
lipophilic cationic dye JC–1 stained mitochondrial membranes
independent of the potential, thereby emitting green fluorescence
(530 nm) reflecting the mitochondrial volume (Mancini et al,
1997). Upon potential-dependent accumulation within the mito-
chondria JC–1 forms aggregates emitting light at 590 nm. ∆ Ψ M is
indicated by 590/530 nm JC–1 emission ratio (Cossarizza et al,
1993). Cells were stained with 1 ml JC–1 (1 µ g ml–1, 15 min,
37˚C) and subsequently washed twice with ice-cold PBS.
Fluorescence was analysed by flow cytometry. To confirm the data
obtained by JC–1 staining, a second mitochondrial dye CMTMRos
(Molecular Probes, Eugene, OR, USA) was used (100 nM, 30 min,
37˚C). The fluorescence emission of CMTMRos stained cells at
590 nm directly correlates with the ∆ Ψ M (Petit et al, 1990). 
Caspase-3 activity assay 
Cells were incubated with medium containing FGIN-1-27, PK
11195, Ro5-4685, FGIN–1-52, or clonazepam at concentrations
from 10 µ M to 100 µ M for 6 h to 16 h, washed twice with PBS, and
stored at –80˚C until use. Approximately 106 cells were lysed with
500 µ l lysis buffer (10 mM Tris-HCl, 10 mM NaH2PO4/Na2HPO4,
130 mM NaCl, 1% Triton-X–100, 10 mM NaPPi, pH 7.5) and total
protein content was quantified using the BCA protein assay kit
(Pierce, Rockford, IL, USA). The activity of caspase-3 was calcu-
lated from the cleavage of the fluorogenic substrate DEVD-AMC
(Nicholson et al, 1995). In brief, 100 µ l cell lysate containing 500
µ g ml–1 protein was incubated with 100 µ l substrate solution (2 µ g
caspase-3 substrate AC-DEVD-AMC, 20 mM HEPES, 10% glyc-
erol, 2 mM DTT, pH 7.5) for 1 h at 37˚C. The cleavage of DEVD-
AMC was measured with a VersaFluor fluorometer (Biorad,
Munich, Germany) using a 360 nm excitation and a 460 nm
emission wavelength. 
Cell cycle analysis 
Cell cycle analysis was performed by the method of Vindelov and
Christensen (Vindelov and Christensen, 1990). 5 × 105 cells per
well were cultured for 24 h and then exposed to PBR ligands for
another 24 h. Cells were trypsinized, washed and the nuclei were
isolated using CycleTest PLUS DNA Reagent Kit (Becton
Dickinson, Heidelberg, Germany). According to the manufacturer’s
instructions DNA was stained with propidium iodide. The DNA
content of the nuclei was detected by flow cytometry and analysed
using CellFit software (Becton Dickinson, Heidelberg, Germany). 
Statistical analysis 
Comparison of multiple means was performed with nonparametric
ANOVA. Comparison of individual drug treatments to control treat-
ments was performed with the unpaired, 2-tailed Mann–Whitney U
test for proliferation, ∆ Ψ M measurements, and caspase-3 activity
experiments. Data are expressed as mean percentage of control
± SEM. For cell cycle analysis the unpaired student’s t-test was
used. P values were considered to be significant at < 0.05. 
RESULTS 
PBR expression in colorectal cancer cells 
The mRNA expression of PBR was investigated by RT-PCR. Both
in HT29 cells and in primary cultures of colorectal carcinomas,
PBR mRNA was detected (Figure 1A). The specificity of the
obtained PCR products was confirmed by direct sequencing of
cDNAs. HT29 cells did not express any β -chain of the GABAA-
receptor (data not shown), which are essential for benzodiazepines
binding to the GABAA-receptor. To investigate the expression of
the PBR protein, cells were stained with the monoclonal anti-PBR
antibody 8D7 and fluorescence was analysed by flow cytometry.
The expression of PBR protein was detected in primary cell
cultures of colorectal cancer cells (Figure 1B), as well as in the cell
lines HT29, LS174T and Colo320 DM (Figure 1C–E). In non-
permeabilized cells, no specific 8D7 fluorescence was observed
indicating an intracellular localization of PBR (Figure 1C–E). 
PBR localization in mitochondria 
To further characterize the subcellular localization of PBR, HT29
cells were simultaneously stained with the mitochondrial dye
CMTMRos and the anti-PBR antibody 8D7. Confocal laser scan-
ning microscopy imaged the subcellular distribution of fluores-
cence. Green fluorescence of 8D7-labelled PBR was detected
within the cytoplasm but neither in the cell membrane nor in the
nucleus (Figure 2A, E). The staining pattern was comparable to the
one obtained by the mitochondrial dye CMTMRos (Figure 2B, I).
Superposition of the images of 8D7-labelled PBR and CMTMRos
stained mitochondria resulted in a yellow colour (Figure 2C) indi-
cating a co-localization of PBR and mitochondria. Likewise, PBR
was localized in the mitochondria in the colorectal cell lines
LS174T and Colo320 DM as well as in primary cultures of 6
resected colorectal cancers (data not shown). To further verify the
mitochondrial localization of PBR, subcellular PBR expression
was immunohistochemically determined in 23 other colorectal
cancers. The differentiation grade of these tumours ranged from
well (n = 1), moderately (n = 13), to poorly (n = 9) differentiated.
PBR and colorectal cancer growth 1773
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distributed within the cytoplasm (Figure 2K, L). No specific PBR
staining was observed in the plasma membrane nor in the nuclei of
cells, indicating that in colorectal cancers PBR is located in the
mitochondria. 
Inhibition of cell proliferation by specific PBR ligands 
Growth-modulating effects of PBR ligands were studied by the
crystal violet assay. The specific PBR ligands FGIN-1-27, PK
11195 and Ro5-4864 (10 µ M to 100 µ M) significantly inhibited
the proliferation of HT29 cells in a dose-dependent manner
(Figure 3). After 72 h of incubation FGIN-1-27 decreased cell
growth with an IC50 = 14 ± 2 µ M, thus showing greater efficacy
than PK 11195 (IC50 = 58 ± 9 µ M) and Ro5-4864 (IC50 = 83 ± 13
µ M). At lower concentrations (1 nM–1 µ M) of FGIN-1-27, PK
11195 or Ro5-4864, no proliferation-modulating effects were
detected, regardless of the presence or absence of serum in the
medium (data not shown). The benzodiazepine clonazepam and
the indoleacetamide FGIN–1-52 were used as control agents.
Despite the similarity of their chemical structures to Ro5-4864 or
FGIN-1-27 (Table 1), respectively, both agents displayed almost
no affinity to PBR (Wang et al, 1984a; Kozikowski et al, 1993). In
contrast to the antiproliferative action of the specific PBR ligands,
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Figure 1 PBR mRNA and protein expression. (A) PBR mRNA expression in HT29 cells (lane 1) and in primary cell cultures of human colorectal cancers (lane
3) was detected by RT-PCR. Negative control was performed by omitting reverse transcriptase (lane 2). (B–E) Flow cytometric analysis of PBR expression in a
primary cell culture of a colorectal cancer (B), and in the colorectal cell lines HT29 (C), LS174T (D), and Colo320 DM (E). Cells were stained with the specific
PBR antibody 8D7 with previous membrane permeabilization (grey area) or without previous membrane permeabilization (grey line, C–E). Black line: isotypic
control clonazepam or FGIN–1-52 caused little if any reduction in prolif-
eration (Figure 3), indicating that the growth-inhibiting effects are
PBR-specific. Likewise to HT29 cells, the specific PBR ligands
inhibited the proliferation of the colorectal cancer cell lines
LS174T and Colo320 DM. After 72 h of incubation FGIN-1-27
decreased the growth of LS174T or Colo320 DM cells with IC50
of 16 ± 2 µ M or of 19 ± 1 µ M, respectively. PK11195 inhibited
cell proliferation with IC50 = 49 ± 4 µ M (LS174T) and IC50 =
53 ± 4 µ M (Colo320 DM), respectively. 
Induction of mitochondrial alterations by specific PBR
ligands 
PBR is located mainly in the outer mitochondrial membrane and is
thought to form the permeability transition pore, which plays an
important role in the regulation of ∆ ψ M. Therefore, we investigated
if specific PBR ligands can modulate the ∆ ψ M and mitochondrial
volume. FGIN-1-27 significantly depolarized the mitochondria
of HT29 cells in a dose-dependent manner as assayed by the
PBR and colorectal cancer growth 1775
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Figure 2 PBR localization in the mitochondria of HT29 cells. (A–J) Confocal laser scanning microscopy simultaneously visualized PBR and mitochondria.
PBR was immunoassayed with the specific monoclonal antibody 8D7 (A, E), and mitochondria were marked with CMTMRos (B, I). Superposition of both
fluorescence images resulted in a bright yellow colour (C), indicating a co-localization of PBR and mitochondria. Specificity of imaging was shown by omitting
CMTMRos staining (F) or using isotypic control antibody (H), respectively. Corresponding transmission light images are shown (D, G, J). Bar = 10 µ M. (K, L)
Sections of paraffin-embedded tumours were immunohistochemically stained with anti-PBR antibody 8D7 and PBR expression was detected using the APAAP
system (red colour). (K) Colorectal carcinoma classified as moderately differentiated. (L) Colorectal carcinoma classified as poorly differentiated. Bar = 100 µ m mitochondrial dye JC–1. Likewise, ∆ ψ M of primary cell cultures of
colorectal cancers was significantly decreased by 50 µ M FGIN-1-
27 (Figure 4A). The results were confirmed by using the mito-
chondrial dye CMTMRos. CMTMRos stained HT29 cells
displayed mean fluorescence of 83 ± 6% (10 µ M), 68 ± 4%
(50 µ M), and 64 ± 6% (100 µ M) of control, respectively, when
incubated for 6 h with FGIN-1-27. Simultaneously, an increase of
mitochondrial volume of HT29 cells and primary cultures was
detected (Figure 4A), indicating that FGIN-1-27 not only induced
a mitochondrial membrane depolarization but also an increase in
mitochondrial volume. In contrast to FGIN-1-27, PK 11195 or
Ro5-4864 showed no effects on HT29 cells after 1 h to 16 h of
incubation. Moreover, the non-PBR-specific compound FGIN–1-
52 did not alter the ∆ ψ M (data not shown). In control experiments
the K+ ionophore valinomycin was used to reduce the JC–1 590
nm fluorescence (Cossarizza et al, 1993) resulting in a mean 590
nm fluorescence of one third of corresponding control. 
Induction of apoptosis by specific PBR ligands 
To date, an involvement of PBR in apoptosis has only been
shown for immune cells (Marchetti et al, 1996a; Hirsch et al,
1998; Bono et al, 1999; Larochette et al, 1999; Ravagnan et al,
1999; Tanimoto et al, 1999) and hepatic stellate cells (Fischer
et al, 2001), but little is known for cancer cells so far. To evaluate
whether the observed antiproliferative effects of PBR ligands were
due to induction of apoptosis caspase-3 activity was investigated. 
Caspase-3 is a key-enzyme in the apoptotic signalling pathway
(Nunez et al, 1998). All 3 tested PBR-specific ligands, FGIN-1-27,
PK 11195 and Ro5-4864, significantly induced an increase in
caspase-3 activity in HT29 cells in a dose-dependent manner.
Whereas FGIN-1-27 induced a maximal activity after 6 h of incu-
bation (Figure 4B), the maximal effect of PK 11195 and Ro5-4864
did not occur before 16 h of incubation (Figure 4C). In contrast,
neither FGIN–1-52 nor clonazepam elevated caspase-3 activity.
Likewise to HT29 cells, FGIN-1-27 and PK11195 dose-dependently
induced caspase-3 activity in the colorectal cancer cell lines LS174T
and Colo320 DM. After 16 h of incubation FGIN-1-27 increased
the caspase-3 activity to 170 ± 27% (50 µ M) and 204 ± 34% (100
µ M) in LS174T cells and to 131 ± 1% (50 µ M) and 160 ± 21%
(100 µ M) in Colo320 DM cells. PK11195 increased the caspase-3
activity to 113 ± 5% (50 µ M) and 219 ± 1% (100 µ M) in LS174T
cells and to 125 ± 8% (50 µ M) and 157 ± 1% (100 µ M) in Colo320
DM cells. Similarly, in primary cell cultures of colorectal cancers 50
µ M FGIN-1-27 elicited a significant increase of caspase-3 activity 
(P < 0.01; Figure 4C).
Induction of cell cycle arrest in G1/G0-phase by PBR
ligands 
To test whether the antiproliferative effects of the PBR ligands are
caused not only by an induction of apoptosis but also by an alter-
ation of cell cycle regulation, we investigated the cell cycle by
propidium iodide staining and subsequent flow cytometry
analysis. The PBR ligands FGIN-1-27, PK 11195 and Ro5-4864
dose-dependently arrested HT29 cells in the G1/G0-phase of cell
cycle (Figure 5) thereby decreasing the proportion of cells in the
S-phase and G2/M-phase. Control experiments with clonazepam or
FGIN–1-52 (up to 100 µ M) showed no alteration in cell cycle. In
LS174T and Colo320 DM cells FGIN-1-27 and PK11195 showed
similar effects. Both ligands induced an arrest in the G1/G0-phase
of the cell cycle in both cell lines. FGIN-1-27 increased the
proportion of cells in the G1/G0-phase from 63 ± 2% (control) to
80 ± 2% (50 µ M) and 84 ± 2% (100 µ M) for LS174T cells, and
from 47 ± 1% (control) to 56 ± 1% (50 µ M) and 61 ± 3%
(100 µ M) for Colo320 DM cells. Similarly, PK11195 increased
the proportion of cells in the G1/G0-phase to 73 ± 1% (50 µ M) and
86 ± 6% (100 µ M) in LS174T cells, and to 51 ± 0.1% (50 µ M)
and 69 ± 5% (100 µ M) in Colo320 DM cells. 
DISCUSSION 
A tightly regulated balance between cell division and cell death is
a prerequisite for normal tissue development. Impaired regulation
of either process can lead to tumorigenesis. In this study we show
that specific PBR ligands induce both an arrest of the cell cycle
and an increase in apoptosis in human colorectal cancer cells. Our
data indicate that PBR might be involved in both the regulation of
cell division and cell death, suggesting an important role of PBR
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Figure 3 Antiproliferative effects of PBR ligands in HT29 cells. The
specific PBR ligands FGIN-1-27 (   ), PK 11195 (   ), and Ro5-4864 (   ) 
dose-dependently inhibited proliferation of HT29 cells as shown for a 72 h
incubation period. Growth inhibition versus control was significant for FGIN-
1-27 and Ro5-4864 from 10 µ M to 100 µ M, and for PK 11195 from 25 µ M to
100 µ M (P < 0.05). In contrast, the GABAA-receptor ligand clonazepam (∆ ) or
the ‘no-affinity’ ligand FGIN-1-52 (× ) showed no or only minor effects. Means
of 4 to 6 independent experiments ± SEM are shown 
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Table 1 Structures and Ki values of FGIN-1-27 and FGIN-1-52. Ki values
indicate the displacement of [3H]4′ -chlorodiazepam from rat cerebellar glial
cell membranes (Kozikowski et al, 1993) in colorectal cancer growth. Moreover, we provide evidence that
the cell cycle interfering and proapoptotic effects of specific
PBR ligands are associated with an inhibition of proliferation of
colorectal cancer cells. 
The PBR is mainly located in the outer membranes of mitochon-
dria (Gavish et al, 1989). Recently, a perinuclear or nuclear localiza-
tion has been described in breast cancer and glioma cells, which was
shown to be associated with an aggressive tumour type (Hardwick
et al, 1999; Brown et al, 2000). Using confocal laser scanning
microscopy and immunohistochemistry, we studied PBR expression
in human colorectal cancers of distinct grades of differentiation, and
in several colorectal cancer cell lines. In all 29 cancers and in the 3
cell lines studied, PBR was found to be localized in the mitochon-
dria. Thus, PBR is primarily targeted to mitochondrial membranes
of either well, moderately or poorly differentiated colorectal
cancers. 
To investigate the functional involvement of PBR in colorectal
cancer growth we used specific exogenous ligands. These ligands
were shown to interfere with the regulation of both the cell cycle
and apoptosis. The specific PBR ligands induced cell cycle arrest.
Upon ligand treatment, the proportion of colorectal cancer cells in
the G1/G0-phase increased markedly, indicating that the cells
PBR and colorectal cancer growth 1777
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Figure 4 Induction of mitochondrial alterations and apoptosis by PBR ligands. (A) After 6 h of incubation with FGIN-1-27 ∆ Ψ M (black columns) and
mitochondrial volume (white columns) of HT29 cells and primary cultures of colorectal tumours were measured using the mitochondrial dye JC-1. ∆ Ψ M is
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PBR ligands act at the classical G1 checkpoint, preventing cells
from entering the S-phase. All 3 PBR ligands studied induced cell
cycle arrest at this restriction point, suggesting a common
signalling pathway. Cell cycle interfering effects of PBR ligands
have been shown previously. In breast cancer PBR ligands induced
a cell cycle arrest at both major restriction points, the G1/S- and
the G2/M-junction (Carmel et al, 1999), whereas in lung and
melanoma cells an accumulation in the G2/M-phase was observed
(Camins et al, 1995; Landau et al, 1998). These differences may
reflect tissue-specific PBR signal transduction. 
In addition to their cell cycle-arresting effects, we here showed
for the first time that specific PBR ligands can induce apoptosis in
non-haematopoietic cancer cells. The PBR ligands FGIN-1-27, PK
11195 and Ro5-4864 stimulated caspase-3 activity in the 3 cell
lines and in all 6 primary cultures of colorectal cancers. Recently,
mitochondrial permeability transition has been described as initi-
ating event in the process of apoptosis (Susin et al, 1998). Within
the mitochondria, PBR is known to be located in the membrane
forming the permeability transition pore (Zorov, 1996). This pore
is considered to play a central role in the initiation of apoptosis
(Zamzami et al, 1995). In this study, the PBR ligand FGIN-1-27
decreased  ∆ ψ M and caused mitochondrial swelling. Whether
FGIN-1-27 induced mitochondrial alterations are a prerequisite for
the induction of apoptosis in colorectal cancer cells is not yet
understood. It has been reported that mitochondrial permeability
transition occurs independently of the initiation of the apoptotic
cascade (Lemasters et al, 1998). The actual role of the mitochon-
drial transition in PBR ligand-induced apoptosis needs to be
further investigated. 
In this study, we showed that the cell cycle-arresting and
proapoptotic effects resulted in an inhibition of cell proliferation.
In line with previous studies in a variety of tumour models
(Garnier et al, 1993; Neary et al, 1995; Landau et al, 1998; Carmel
et al, 1999; Beinlich et al, 1999), the specific PBR ligands FGIN-
1-27, PK 11195 and Ro5-4864 exhibited antiproliferative effects
in colorectal cancer cells at micromolar concentrations. To clarify
the PBR specificity of the observed effects, we used the benzodi-
azepine clonazepam or the indoleacetamide FGIN–1-52. Despite
their very similar structure to Ro5-4864 or FGIN-1-27, respec-
tively, neither clonazepam nor FGIN–1-52 affected apoptosis, cell
cycle or the proliferation of human colorectal cancer cells. This
indicates that the effects are specific for PBR. Nevertheless, there
is a quantitative discrepancy between the micromolar ligand
concentrations necessary to inhibit cell proliferation and the
nanomolar-binding affinities. This discrepancy might be due to the
existence of a putative ‘low-affinity PBR’ which has previously
been suggested to exist in other tissues (Pawlikowski et al, 1988;
Kunert-Radek et al, 1994). This putative low-affinity binding site
has been implied in the regulation of calcium channels (Cantor et
al, 1984; Taft and DeLorenzo, 1984), suggesting that PBR ligands
might affect calcium influx responsible for growth inhibition.
However, other factors including cellular absorption, ligand
metabolism, as well as differences in the conditions used for the
cell proliferation and binding assays (Wang et al, 1984b) have yet
to be ruled out. 
Even though the exact targets and mechanisms of the proapop-
totic and antiproliferative effects of the specific PBR ligands remain
to be elucidated, the ability of these ligands to modulate both apop-
tosis and cell cycle regulation qualify them as promising agents for
innovative treatment strategies in colorectal cancer disease. 
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